MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
CareDx, Inc Total Assets 2011-2026 | CDNA
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets CareDx, Inc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 413 M | 491 M | 467 M | 543 M | 567 M | 369 M | 152 M | 131 M | 83.6 M | 76.7 M | 55.6 M | 61.1 M | 9.87 M | 9.88 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 567 M | 9.87 M | 245 M |
Quarterly Total Assets CareDx, Inc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 432 M | 444 M | 490 M | 491 M | 477 M | 467 M | 452 M | 467 M | 501 M | 515 M | 528 M | 543 M | 545 M | - | 547 M | 567 M | 563 M | 557 M | 541 M | 369 M | 369 M | 369 M | 369 M | 152 M | 152 M | 152 M | 152 M | 131 M | 131 M | 131 M | 131 M | 83.6 M | 83.6 M | 83.6 M | 83.6 M | 76.7 M | 76.7 M | 76.7 M | 76.7 M | 55.6 M | 55.6 M | 55.6 M | 55.6 M | 61.1 M | 61.1 M | 61.1 M | 61.1 M | 9.87 M | 9.87 M | 9.87 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 567 M | 9.87 M | 263 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 98.33 | 0.9 % | $ 8.11 B |  Irlanda |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 13.71 | -0.22 % | $ 99.4 M |  Israel |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 155.46 | 1.83 % | $ 7.71 B | USA |
 |
Bioventus
BVS
|
684 M | $ 8.62 | 0.23 % | $ 574 M | USA |
 |
DexCom
DXCM
|
6.34 B | $ 64.24 | -1.56 % | $ 25.1 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
531 M | $ 25.56 | 0.95 % | $ 710 M | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | $ 103.57 | 0.29 % | $ 19.5 B | USA |
 |
Guardant Health
GH
|
2.01 B | $ 85.49 | 1.75 % | $ 10.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 14.77 | 0.61 % | $ 447 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 17.88 | -6.63 % | $ 2.32 B | USA |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 2.83 | -1.05 % | $ 91.8 K | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 187.32 | 0.57 % | $ 134 B | USA |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 164.72 | 1.1 % | $ 28.3 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 118.94 | 2.92 % | $ 18.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 199.7 | -0.46 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
10.7 B | $ 111.51 | -0.06 % | $ 33.9 B | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.11 | -0.89 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 9.0 | -0.99 % | $ 255 M | Israel |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 9.09 | -2.78 % | $ 1.97 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 16.52 | 0.12 % | $ 370 M | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.33 | 4.72 % | $ 399 M | USA |
 |
Co-Diagnostics
CODX
|
95.3 M | - | - | $ 79.8 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 450.41 | 1.48 % | $ 13 B | USA |
 |
Celcuity
CELC
|
245 M | $ 114.22 | 3.11 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 173.74 | 0.49 % | $ 24.2 B |  Schweiz |
 |
Personalis
PSNL
|
270 M | $ 6.72 | 1.97 % | $ 398 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 7.88 | -1.25 % | $ 1.01 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
1.39 B | $ 187.85 | -1.29 % | $ 18.5 B | USA |
 |
Sotera Health Company
SHC
|
3.26 B | $ 13.42 | 0.71 % | $ 3.81 B | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
OPKO Health
OPK
|
2.2 B | $ 1.19 | 2.59 % | $ 826 M | USA |